» Articles » PMID: 37653478

Status of Diagnosis and Preventative Treatment for Primary Headache Disorders: Real-world Data of Unmet Needs in China

Abstract

Background: Headache disorders are widely prevalent and pose a considerable economic burden on individuals and society. Globally, misdiagnosis and inadequate treatment of primary headache disorders remain significant challenges, impeding the effective management of such conditions. Despite advancements in headache management over the last decade, a need for comprehensive evaluations of the status of primary headache disorders in China regarding diagnosis and preventative treatments persists.

Methods: In the present study, we analyzed the established queries in the Survey of Fibromyalgia Comorbidity with Headache (SEARCH), focusing on previous diagnoses and preventative treatment regimens for primary headache disorders. This cross-sectional study encompassed adults diagnosed with primary headache disorders who sought treatment at 23 hospitals across China between September 2020 to May 2021.

Results: The study comprised 2,868 participants who were systematically examined. Migraine and tension-type headaches (TTH) constituted a majority of the primary headache disorders, accounting for 74.1% (2,124/2,868) and 23.3% (668/2,868) of the participants, respectively. Medication overuse headache (MOH) affected 8.1% (231/2,868) of individuals with primary headache disorders. Over half of the individuals with primary headache disorders (56.6%, 1,624/2,868) remained undiagnosed. The previously correct diagnosis rates for migraine, TTH, TACs, and MOH were 27.3% (580/2,124), 8.1% (54/668), 23.2% (13/56), and 3.5% (8/231), respectively. The misdiagnosis of "Nervous headache" was found to be the most prevalent among individuals with migraine (9.9%, 211/2,124), TTH (10.0%, 67/668), trigeminal autonomic cephalalgias (TACs) (17.9%, 10/56), and other primary headache disorders (10.0%, 2/20) respectively. Only a minor proportion of individuals with migraine (16.5%, 77/468) and TTH (4.7%, 2/43) had received preventive medication before participating in the study.

Conclusions: While there has been progress made in the rate of correct diagnosis of primary headache disorders in China compared to a decade ago, the prevalence of misdiagnosis and inadequate treatment of primary headaches remains a veritable issue. As such, focused efforts are essential to augment the diagnosis and preventive treatment measures related to primary headache disorders in the future.

Citing Articles

Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine.

Li M, Huang S, Li J, Hu X, Chen J Drug Des Devel Ther. 2025; 19:1231-1247.

PMID: 39991088 PMC: 11847418. DOI: 10.2147/DDDT.S499848.


The quality and reliability of online video resources concerning patient education for migraine treatment in China Mainland: an electronic media-based study.

Ge R, Xu X, Chen Y, You S, Xu J, Dai H BMC Public Health. 2025; 25(1):656.

PMID: 39966862 PMC: 11834577. DOI: 10.1186/s12889-025-21861-x.


Consistency between headache diagnoses and ICHD-3 criteria across different levels of care.

Overeem L, Ulrich M, Fitzek M, Lange K, Hong J, Reuter U J Headache Pain. 2025; 26(1):6.

PMID: 39789456 PMC: 11715415. DOI: 10.1186/s10194-024-01937-6.


First real-world study on the effectiveness and tolerability of rimegepant for acute migraine therapy in Chinese patients.

Yang Z, Wang X, Niu M, Wei Q, Zhong H, Li X J Headache Pain. 2024; 25(1):160.

PMID: 39333875 PMC: 11438109. DOI: 10.1186/s10194-024-01873-5.


Clinical decision support system using hierarchical fuzzy diagnosis model for migraine and tension-type headache based on International Classification of Headache Disorders, 3rd edition.

Yin Z, Li H, Han X, Ran Y, Wang Z, Dong Z Front Neurol. 2024; 15:1444197.

PMID: 39318875 PMC: 11420035. DOI: 10.3389/fneur.2024.1444197.


References
1.
Saylor D, Steiner T . The Global Burden of Headache. Semin Neurol. 2018; 38(2):182-190. DOI: 10.1055/s-0038-1646946. View

2.
Ashina M, Katsarava Z, Do T, Buse D, Pozo-Rosich P, Ozge A . Migraine: epidemiology and systems of care. Lancet. 2021; 397(10283):1485-1495. DOI: 10.1016/S0140-6736(20)32160-7. View

3.
Liu R, Yu S, He M, Zhao G, Yang X, Qiao X . Health-care utilization for primary headache disorders in China: a population-based door-to-door survey. J Headache Pain. 2013; 14:47. PMC: 3673891. DOI: 10.1186/1129-2377-14-47. View

4.
Yu S, Liu R, Zhao G, Yang X, Qiao X, Feng J . The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache. 2012; 52(4):582-91. DOI: 10.1111/j.1526-4610.2011.02061.x. View

5.
Li X, Zhou J, Tan G, Wang Y, Ran L, Chen L . Diagnosis and treatment status of migraine: a clinic-based study in China. J Neurol Sci. 2011; 315(1-2):89-92. DOI: 10.1016/j.jns.2011.11.021. View